- Home
- XYL vs ONC Comparison
XYL vs ONC Comparison
Compare XYL & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XYL
- ONC
- Stock Information
- Founded
- XYL 2011
- ONC 2010
- Country
- XYL United States
- ONC Switzerland
- Employees
- XYL N/A
- ONC N/A
- Industry
- XYL Fluid Controls
- ONC Biotechnology: Pharmaceutical Preparations
- Sector
- XYL Industrials
- ONC Health Care
- Exchange
- XYL Nasdaq
- ONC Nasdaq
- Market Cap
- XYL 31.5B
- ONC 26.9B
- IPO Year
- XYL N/A
- ONC N/A
- Fundamental
- Price
- XYL $130.94
- ONC $250.30
- Analyst Decision
- XYL Buy
- ONC Strong Buy
- Analyst Count
- XYL 8
- ONC 9
- Target Price
- XYL $143.71
- ONC $325.56
- AVG Volume (30 Days)
- XYL 1.3M
- ONC 345.1K
- Earning Date
- XYL 07-31-2025
- ONC 08-06-2025
- Dividend Yield
- XYL 1.22%
- ONC N/A
- EPS Growth
- XYL 30.51
- ONC N/A
- EPS
- XYL 3.71
- ONC N/A
- Revenue
- XYL $8,598,000,000.00
- ONC $4,175,868,000.00
- Revenue This Year
- XYL $3.24
- ONC $869.15
- Revenue Next Year
- XYL $4.79
- ONC $19.07
- P/E Ratio
- XYL $35.30
- ONC N/A
- Revenue Growth
- XYL 8.16
- ONC 51.16
- 52 Week Low
- XYL $100.48
- ONC $146.21
- 52 Week High
- XYL $143.50
- ONC $287.88
- Technical
- Relative Strength Index (RSI)
- XYL 60.04
- ONC N/A
- Support Level
- XYL $130.39
- ONC N/A
- Resistance Level
- XYL $132.52
- ONC N/A
- Average True Range (ATR)
- XYL 1.99
- ONC 0.00
- MACD
- XYL 0.11
- ONC 0.00
- Stochastic Oscillator
- XYL 81.13
- ONC 0.00
About XYL Xylem Inc. New
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $8.6 billion in revenue in 2024.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.